The first healthy volunteers have been dosed in an early clinical trial testing NRG5051, a disease-modifying therapy for ALS ...
The European regulator’s anniversary year featured first-in-class therapies, rare-disease advances, safety warnings, and new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback